Relevant bibliographies by topics / Pharmaceutical industry Australia Case studies

Academic literature on the topic 'Pharmaceutical industry Australia Case studies'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical industry Australia Case studies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical industry Australia Case studies"

1

Mirabelli-Montan, Ysadora A., Matteo Marangon, Antonio Graça, Christine M. Mayr Marangon, and Kerry L. Wilkinson. "Techniques for Mitigating the Effects of Smoke Taint While Maintaining Quality in Wine Production: A Review." Molecules 26, no. 6 (March 17, 2021): 1672. http://dx.doi.org/10.3390/molecules26061672.

Full text
Abstract:
Smoke taint has become a prominent issue for the global wine industry as climate change continues to impact the length and extremity of fire seasons around the world. Although the issue has prompted a surge in research on the subject in recent years, no singular solution has yet been identified that is capable of maintaining the quality of wine made from smoke-affected grapes. In this review, we summarize the main research on smoke taint, the key discoveries, as well as the prevailing uncertainties. We also examine methods for mitigating smoke taint in the vineyard, in the winery, and post production. We assess the effectiveness of remediation methods (proposed and actual) based on available research. Our findings are in agreement with previous studies, suggesting that the most viable remedies for smoke taint are still the commercially available activated carbon fining and reverse osmosis treatments, but that the quality of the final treated wines is fundamentally dependent on the initial severity of the taint. In this review, suggestions for future studies are introduced for improving our understanding of methods that have thus far only been preliminarily investigated. We select regions that have already been subjected to severe wildfires, and therefore subjected to smoke taint (particularly Australia and California) as a case study to inform other wine-producing countries that will likely be impacted in the future and suggest specific data collection and policy implementation actions that should be taken, even in countries that have not yet been impacted by smoke taint. Ultimately, we streamline the available information on the topic of smoke taint, apply it to a global perspective that considers the various stakeholders involved, and provide a launching point for further research on the topic.
APA, Harvard, Vancouver, ISO, and other styles
2

Bagheri, Mohammad B., and Matthias Raab. "Subsurface engineering of CCUS in Australia (case studies)." APPEA Journal 59, no. 2 (2019): 762. http://dx.doi.org/10.1071/aj18125.

Full text
Abstract:
Carbon capture utilisation and storage (CCUS) is a rapidly emerging field in the Australian oil and gas industry to address carbon emissions while securing reliable energy. Although there are similarities with many aspects of the oil and gas industry, subsurface CO2 storage has some unique geology and geophysics, and reservoir engineering considerations, for which we have developed specific workflows. This paper explores the challenges and risks that a reservoir engineer might face during a field-scale CO2 injection project, and how to address them. We first explain some of the main concepts of reservoir engineering in CCUS and their synergy with oil and gas projects, followed by the required inputs for subsurface studies. We will subsequently discuss the importance of uncertainty analysis and how to de-risk a CCUS project from the subsurface point of view. Finally, two different case studies will be presented, showing how the CCUS industry should use reservoir engineering analysis, dynamic modelling and uncertainty analysis results, based on our experience in the Otway Basin. The first case study provides a summary of CO2CRC storage research injection results and how we used the dynamic models to history match the results and understand CO2 plume behaviour in the reservoir. The second case study shows how we used uncertainty analysis to improve confidence on the CO2 plume behaviour and to address regulatory requirements. An innovative workflow was developed for this purpose in CO2CRC to understand the influence of each uncertainty parameter on the objective functions and generate probabilistic results.
APA, Harvard, Vancouver, ISO, and other styles
3

Kinter, L. "Exploratory fim studies – case studies & perspectives from the pharmaceutical industry." Toxicology Letters 205 (August 2011): S2. http://dx.doi.org/10.1016/j.toxlet.2011.05.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Qureshi, Athar Mahmood Ahmed, and Nina Evans. "Deterrents to knowledge-sharing in the pharmaceutical industry: a case study." Journal of Knowledge Management 19, no. 2 (April 7, 2015): 296–314. http://dx.doi.org/10.1108/jkm-09-2014-0391.

Full text
Abstract:
Purpose – This study aims to explore deterrents to knowledge-sharing in pharmaceutical manufacturing. Effective knowledge-sharing is fundamental to stimulation of the process of knowledge absorption. The limited proximal communication between the employees in the pharmaceutical industry stifles their knowledge-sharing behaviour significantly. Design/methodology/approach – A cross-sectional case study, consisting of semi-structured interviews with managers and scientists, was conducted in a multinational pharmaceutical company in Australia. Respondents were asked to answer questions regarding their current knowledge-sharing practices and to identify organisational deterrents to knowledge-sharing. The data were condensed into themes according to the thematic analysis method. Findings – The pharmaceutical industry is extensively regulated and its excessive competitiveness is cultivating organisational reticence towards the development of a knowledge-sharing culture. Nine categories of deterrents to intra- (within) and inter-organisational (between organisations) knowledge-sharing have been identified. These categories include high cost of sharing knowledge, information technology limitations, knowledge-hiding, lack of socialisation, lack of trust culture, non-educational mindset, organisational politics, poor leadership and time pressure. Research limitations/implications – The population of this study consists of managers and practitioners working for a pharmaceutical company. Hence, the generalisability of the findings to other health-care settings is unknown. Practical implications – The findings have implications for leaders and managers who should be aware of these professional diversities, instigators as well as the ripple effects of limited knowledge-sharing to guide the organisation towards developing an optimal knowledge-sharing culture. Originality/value – A focussed investigation of knowledge-sharing behaviour within the pharmaceutical industry in Australia, considering the pressure applied to this industry over the past decade. This case study specifically focusses on the diversity of deterrents to knowledge-sharing in the pharmaceutical manufacturing industry.
APA, Harvard, Vancouver, ISO, and other styles
5

Murray, Virginia S. "Technological Change in the Postproduction Film Industry: Case Studies in Melbourne, Australia." International Journal of the Humanities: Annual Review 4, no. 7 (2007): 1–8. http://dx.doi.org/10.18848/1447-9508/cgp/v04i07/41967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Murray, Virginia S. "Mothering in the Freelance Film Industry: Case Studies in the Postproduction Film Industry in Melbourne, Australia." International Journal of the Arts in Society: Annual Review 2, no. 2 (2007): 73–80. http://dx.doi.org/10.18848/1833-1866/cgp/v02i02/35379.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Danese, Pamela, Pietro Romano, and Andrea Vinelli. "Sequences of improvement in supply networks: case studies from the pharmaceutical industry." International Journal of Operations & Production Management 26, no. 11 (November 2006): 1199–222. http://dx.doi.org/10.1108/01443570610705827.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Eastwood, Brian J. "Applied Statistics in the Pharmaceutical Industry With Case Studies Using S-PLUS." Journal of the American Statistical Association 98, no. 461 (March 2003): 250. http://dx.doi.org/10.1198/jasa.2003.s253.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Brayshaw, Nigel. "Applied Statistics in the Pharmaceutical Industry, with Case Studies in S-Plus." Journal of the Royal Statistical Society: Series D (The Statistician) 52, no. 2 (July 2003): 243–44. http://dx.doi.org/10.1111/1467-9884.t01-1-00356.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kaino, Lorna. "The ‘Problem of Culture’: A Case Study of Some Arts Industries in Southwest Western Australia." Media International Australia 101, no. 1 (November 2001): 127–39. http://dx.doi.org/10.1177/1329878x0110100114.

Full text
Abstract:
This paper presents a case study of three glass art studios situated in the southwest of Western Australia. The study is designed to provide a model for a larger study of the arts industries that will contribute to a strategic analysis of cultural policies for arts industry development. Its purpose is to offer insights into why arts policy frameworks and arts development strategies in the southwest of Western Australia appear to have had limited outcomes consistent with their arts industry objectives. It proposes that one of the reasons — difficult to formalise in policy documents but a persistent theme in informal discussions I have had with arts practitioners all over the southwest region — is a conceptual problem related to instrumentalities charged with the responsibility of implementing arts policy and development. I propose that this is a ‘problem of culture ‘. I explore this proposition in relation to cultural policy planning and development at the regional level within a wider framework at the state and federal levels in Australia and internationally.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical industry Australia Case studies"

1

Govinnage, Sunil Kantha. "Environmental Regulations of the Mining Industry: Two Case Studies from Western Australia." Thesis, Curtin University, 2018. http://hdl.handle.net/20.500.11937/75445.

Full text
Abstract:
The study analyses the Western Australian mining regulatory framework of environmental compliance. Through the case studies of Yeelirrie uranium mining approval, and Collie coal mining, it identifies a dichotomy (Acts of Parliament and State Agreements) of mining legislation and multi-agency approach challenging effective environmental protection. Grounded in sustainability and social sciences approaches, the thesis draws from expert interviews to identify weaknesses and best practices. It makes recommendations for strengthening the implementation of the mining regulatory framework.
APA, Harvard, Vancouver, ISO, and other styles
2

Sweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme." full-text, 2008. http://eprints.vu.edu.au/1960/1/sweeny.pdf.

Full text
Abstract:
This thesis investigates the contribution to the growth in expenditure on medicines listed on the Pharmaceutical Benefits Scheme (PBS) from three inter-related sources: (i) the addition of new medicines offering an expanding range of treatments for disease, (ii) PBS processes for determining the prices of medicines and their conditions of listing and (iii) the demand by patients for PBS medicines. In doing so it uses trend analysis presented in both tabular and graphic form, expenditure decomposition techniques based on index and indicator numbers, and econometric analysis. Using novel techniques and interpretations, it addresses some key aspects of decomposition analysis including the treatment of new and disappearing goods and the potential bias arising from changing market shares among substitutable medicines. The analysis is undertaken for the period from 1991-92 to 2005-06. An important consequence of the cost-effectiveness and reference pricing techniques used by the PBS, is that the quantity index calculated within the decomposition of PBS expenditure can be interpreted as a measure of the quality-adjusted amount of medicines consumed by patients. This is virtually equivalent to the growth in expenditure of about 12% per annum. On average prices of medicines fell over time, modestly in nominal terms and to a greater extent in real terms. Based on the results of econometric analysis, new evidence is presented on the relative influences of copayments, safety net limits, the number of PBS medicines listed and their conditions of listing on the demand for PBS medicines by different categories of patients. Elasticities with respect to patient price are in the range -1.1 to -1.4 for General Non-Safety Net patients and in the range -0.5 to -0.9 for Concessional Non-Safety Net patients.
APA, Harvard, Vancouver, ISO, and other styles
3

Linden, Luan Paula. "Pharmaceutical industry perspectives on factors that influence the adoption and diffusion of drugs in the UK : four case studies." Thesis, University of Birmingham, 2014. http://etheses.bham.ac.uk//id/eprint/4897/.

Full text
Abstract:
Aim: To gather, analyse and present the views of personnel currently working within pharmaceutical companies relating to factors influencing drug diffusion (market penetration), using case studies to determine how their perspective relates to diffusion curves and literature-based timelines describing the same phenomenon. Methods: Qualitative study based on semi-structured interviews with marketing, market access or senior management personnel from eight major UK R&D pharmaceutical companies. Case studies were selected through expert consultation. Diffusion curves were produced for all potential case study drugs (n=21) and timelines constructed from the literature and augmented with clinical expert input. Results: Thematic analysis of 15 interviews conducted across four case studies: bisphosphonates; atypical anti psychotics; phosphodiesterase type 5 inhibitors and statins revealed 10 diffusion themes: clinical need; clinician/patient experience; clinical evidence; health service/policy environments; adopter attitudes; communicating relative advantage; market development; opinion leaders; company culture/ heritage and pricing. Triangulation with diffusion curves and literature-based timelines demonstrated a high level of convergence between accounts. Points of divergence revealed unique pharmaceutical industry insights. Conclusion: Eliciting diffusion knowledge from this under-researched stakeholder group largely confirmed issues previously outlined in the literature, but importantly has revealed the significance of less tangible social interactions that inform perceptions of new pharmaceuticals that can significantly influence adoption and diffusion.
APA, Harvard, Vancouver, ISO, and other styles
4

Windsor, Carol A. "Industry policy, finance and the AIDC : Australia from the 1950s to the 1970s." Thesis, University of Queensland, 2009. http://espace.library.uq.edu.au/view/UQ:189307.

Full text
Abstract:
This thesis, conceived within a Marxist framework, addresses key conceptual issues in the writing and theorising on industry policy in post second world- war Australia. Broadly, the thesis challenges the way that industry policy on the left of politics (reflected in the social democratic and Keynesian positions) has been constructed as a practical, progressive policy agenda. Specifically, the thesis poses a direct challenge to the primacy of the ‘national’ in interpreting the history of industry policy. The challenge is to the proposition that conflicts between national industry and international finance arose only from the mid 1980s. On the contrary, as will be seen, this is a 1960s issue and any interpretation of the debates and the agendas surrounding industry policy in the 1980s must be predicated on an understanding of how the issue was played out two decades earlier. As was the case in the 1960s, industry policy in the 1980s has been isolated from two key areas of interrogation: the role of the nation state in regulating accumulation and the role of finance in industry policy. In the 1950s and more so in the 1960s and early 1970s there was a reconfiguration of financing internationally but it is one that did not enter into industry policy analysis. The central concern therefore is to simultaneously sketch the historical political economy on industry policy from the 1950s through to the early 1970s in Australia and to analytically and empirically insert the role of finance into that history. In so doing the thesis addresses the economic and social factors that shaped the approach to industry finance in Australia during this critical period. The analysis is supported by a detailed examination of political and industry debates surrounding the proposal for, and institution of, a key national intervention in the form of the Australian Industry Development Corporation (AIDC).
APA, Harvard, Vancouver, ISO, and other styles
5

Sweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme." Thesis, full-text, 2008. https://vuir.vu.edu.au/1960/.

Full text
Abstract:
This thesis investigates the contribution to the growth in expenditure on medicines listed on the Pharmaceutical Benefits Scheme (PBS) from three inter-related sources: (i) the addition of new medicines offering an expanding range of treatments for disease, (ii) PBS processes for determining the prices of medicines and their conditions of listing and (iii) the demand by patients for PBS medicines. In doing so it uses trend analysis presented in both tabular and graphic form, expenditure decomposition techniques based on index and indicator numbers, and econometric analysis. Using novel techniques and interpretations, it addresses some key aspects of decomposition analysis including the treatment of new and disappearing goods and the potential bias arising from changing market shares among substitutable medicines. The analysis is undertaken for the period from 1991-92 to 2005-06. An important consequence of the cost-effectiveness and reference pricing techniques used by the PBS, is that the quantity index calculated within the decomposition of PBS expenditure can be interpreted as a measure of the quality-adjusted amount of medicines consumed by patients. This is virtually equivalent to the growth in expenditure of about 12% per annum. On average prices of medicines fell over time, modestly in nominal terms and to a greater extent in real terms. Based on the results of econometric analysis, new evidence is presented on the relative influences of copayments, safety net limits, the number of PBS medicines listed and their conditions of listing on the demand for PBS medicines by different categories of patients. Elasticities with respect to patient price are in the range -1.1 to -1.4 for General Non-Safety Net patients and in the range -0.5 to -0.9 for Concessional Non-Safety Net patients.
APA, Harvard, Vancouver, ISO, and other styles
6

Letsitsi, Ezekiel Tebogo. "Waste management in the pharmaceutical industry : an evaluation report of Dr Reddy's Laboratories." Thesis, Rhodes University, 2013. http://hdl.handle.net/10962/d1001872.

Full text
Abstract:
The pharmaceutical industry must worry about managing pharmaceutical waste as it poses a health risk to human beings and its presence in the environment can also contribute to loss of biodiversity. Ngwuluka, Ochekpe, and Odumosu (2011: 11259) state that “Pharmaceuticals, though used to treat and manage diseases, are poisons, which justify the growing concerns about their presence in the environment.” Various forms of pharmaceutical waste exist, Ngwuluka et al. (2011) identified the following forms of pharmaceutical waste: Expired dosage forms, non-reworkable formulations, spilled pharmaceuticals, rejected active pharmaceutical ingredients, expired active pharmaceutical ingredients, and wastewater resulting from the water used for process operations during manufacturing and could come from the water used to clean equipment, pipes and floors, and would contain amongst other materials, chemicals and active pharmaceutical ingredients (APIs). A review on the pharmaceutical industry and the progress they have made in environmental management by generating health, safety and environmental programs, preventing pollution, waste minimization, recycling and reusing materials, investing in projects and facilities to ensure environmental sustainability have been established (Berry & Rondinelli, 2000). Dr. Reddy’s Laboratories is an Indian based pharmaceutical company which imports, markets and sells medicines in South Africa. Dr. Reddy’s has plans to set up a manufacturing plant in South Africa. The purpose of this study is to research waste management practices at Dr. Reddy’s plant in India and to draw parallels between India’s and South Africa’s waste legislation. This is to enable Dr. Reddy’s to review all aspects of its waste management systems, in order to revise where necessary and to improve the overall achievement of its waste management objectives in order to become a more sustainable organisation and to meet South African Waste legislation before setting up a plant in South Africa. 3 ii. Objective of the Evaluation Report The purpose of this research is to evaluate and analyse the development and implementation of a waste management system in a pharmaceutical company, specifically Dr. Reddy’s Laboratories. This is primarily to enable the company to review and analyse all aspects of waste management pertaining to pharmaceutical manufacturing and to revise or improve where necessary to ensure adherence to waste regulations as outlined by government. The following research goals have been also been identified:  To identify and describe waste management practices at Dr. Reddy’s Laboratories, on the inherent assumption by the researcher that the company has a successful waste management strategy that would need to be reviewed to identify areas of improvement before expanding manufacturing facilities into South Africa.  To evaluate, assess and compare similarities and/or differences between the identified South African Legislation for Waste Management with those identified during research conducted at Dr. Reddy’s iii. Importance of the Research Conducted Waste Management is important in that it not only removes from the environment, substances that can be harmful to humans and animals but it also enables an organisation to be more sustainable. According to Seadon (2010: i) “Integrated waste management is considered from a systems’ approach, with a particular emphasis on advancing sustainability”. The study will provide guidance to senior management, shop floor managers and employees who work in Dr. Reddy’s manufacturing plants as well as overall employees at Dr. Reddy’s on how to successfully implement a Waste Management programme to enhance sustainability at the organisation and realise the benefits to the organisation of being more sustainable. Weybrecht (2010) identified the following benefits that companies could gain by adopting sustainable waste management practices: reduced costs, resource preservation, keeping up with legislation, enhanced reputation, business differentiation from competitors, and attraction and retention of quality employees, and customer need satisfaction amongst many other benefits. This research needs to address the gap in analysing waste management practices (with more emphasis on waste treatment, waste minimisation, re-use, recycling and disposal), and implementation and understanding of waste management in the pharmaceutical industry as prior research was done mostly in other chemical industries and not to a large scale in the pharmaceutical industry. South African Waste Legislation, Indian Waste Legislation (as Dr. Reddy’s is based in India), as well as International Pharmaceutical Waste Management Guidelines, and International Pharmaceutical Good Manufacturing Practices provide a framework and benchmark of leading pharmaceutical waste management practices that can guide Dr. Reddy’s Laboratories’ leadership into integrating their waste management practices into their plans of setting up a manufacturing plant in South Africa. 5. Research Methodology This is evaluation research in the form of a case study and the data collection method employed is the conduction of a survey through questionnaires. The evaluation research also involves a document analysis of the organisation’s 2011 and 2012 annual reports, Dr. Reddy’s 2010 Sustainability Report as well as literature compiled by the organisation’s Corporate Communications Division. The research would also include review of existing literature on waste management. v. Structure of Dissertation This dissertation consists of three sections. Section 1: The Evaluation Report The section introduces the research area, provides the objectives of the research, provides contextual background information and describes the rationale for conducting the research. This section further describes Dr. Reddy’s waste management practice as outlined in relevant company documentation; it is also intended to highlight the specific waste management processes that were followed in the formulation and implementation of the waste management strategy. This section further describes the sample and presents the results of the survey, where the results are collated and reviewed in the context of the criteria set in the South African Waste Legislation, Indian Waste Legislation, as well as in International Pharmaceutical Waste Management Guidelines, and International Pharmaceutical Good Manufacturing Practices. The overall findings of this case study suggest that although management at Dr. Reddy’s are satisfied with waste management practices and results achieved at it manufacturing plant, there is however dissatisfaction amongst employees who believe the organisation has not successfully disseminated information and sufficiently trained them on waste management policies, processes and practices. There is therefore a desire amongst employees to be trained and to see the company improve on its waste management processes, this desire is a very important attribute as it indicates that employees at Dr. Reddy understand and are committed to the importance of waste management. Future research should be conducted to measure the legal impact of non-compliance to legislation governing waste management in the pharmaceutical company. Section 2: Literature Review The objective of the literature review is to provide a critical assessment and evaluation of previous research in the field of waste management in general as prior research was done mostly in other industries and not to a large scale in the pharmaceutical industry. The literature review evaluates the key elements of an effective waste management strategy implementation and is followed by a review of literature pertaining to the description of Pharmaceutical waste. Section 3: Research Methodology This section presents a description of how the work in this research was conducted. It presents the research process followed in compiling this case study, represented by the aims and objectives, research methodology and design, data collection techniques and data analysis.
APA, Harvard, Vancouver, ISO, and other styles
7

Thomas, Roseanne. "Implications of electronic ordering in the Australian fresh foods industry: A longitudinal study of an Australian smallgoods company 1999-2005." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2007. https://ro.ecu.edu.au/theses/315.

Full text
Abstract:
The literature about information systems adoption generally, and specifically the use of EOI within supply chains. indicates that there are significant savings to be made, primarily by reductions in inventory costs. The Iiterature surrounding the Efficient Consumer Response (ECR) movement within the retail supply chain also claims that there are significant savings to be made and that these savings will be shared by partners within the supply chain and be passed on to consumers. This is a two stage study of a local case organisation operating within a duopoly industry environment. The research was conductad during the period of 1999 to 2005.
APA, Harvard, Vancouver, ISO, and other styles
8

Chan, Leong. "Developing a Strategic Policy Choice Framework for Technological Innovation: Case of Chinese Pharmaceuticals." PDXScholar, 2013. https://pdxscholar.library.pdx.edu/open_access_etds/1041.

Full text
Abstract:
With the growing trend of globalization and rapid development of high technologies, emerging economies face more challenges in technology development because they are chasing a fast-moving frontier. They need to identify global technology trends and adapt to local needs and capabilities. Strategies for technology development differ among countries at different developmental stages. In this research, a technology policy choice framework is developed to link prospective high-tech areas, technology development strategies, and various innovative resources. The research approach is to develop a hierarchical decision model (HDM) and apply the analytic hierarchical process (AHP). Experts are invited from diverse sources to provide a balanced perspective representing different stakeholders. This research focuses on the fast developing Chinese biopharmaceutical industry as a case study. The results of this research have identified thirteen prospective biotech areas that China should invest more resources for development. These technology areas include: recombinant therapeutic proteins, recombinant vaccines, monoclonal antibody technology, cell and tissue engineering, gene therapy, antisense therapy, RNAi, nanobiotechnology, synthetic biology, bioinformatics, pharmacogenetics, gene sequencing, and biotechnology diagnostics. For most of these technology areas, the results have indicated an imitative innovation strategy should be taken as a better strategy under current technological conditions in China. The research has further found that high-tech small-to-medium companies and multinational corporations are major innovation contributors in the Chinese biopharmaceutical sector. The research outcomes can serve as guidelines in resource allocation and policy making for technology development. Based on the overall research findings, policy-makers can apply more specific policy instruments to support innovation activities. Appropriate policy measures may help the country to construct an innovative ecosystem that can serve as the driving force for future technology development.
APA, Harvard, Vancouver, ISO, and other styles
9

Novais, Santos Jose. "An interaction and network perspective of horizontal relationships in the portuguese pharmaceutical industry." Doctoral thesis, Instituto Superior de Economia e Gestão, 2016. http://hdl.handle.net/10400.5/11950.

Full text
Abstract:
Doutoramento em Gestão
Os relacionamentos horizontais, como sejam as alianças estratégicas, são cada vez mais importantes e prevalecentes. O propósito desta investigação é a compreensão do desenvolvimento de relacionamentos horizontais, utilizando a perspetiva de interação e redes. Foi desenvolvida investigação de relevo em alianças estratégicas salientando as motivações, antecedentes, formação e resultados. Todavia, os investigadores têm vindo a descurar os processos de desenvolvimento destes relacionamentos. Para o objetivo da investigação são considerados dois quadros conceptuais complementares, focando tanto a interação, como o desenvolvimento dos relacionamentos. É considerada uma estratégia de caso de estudo múltiplo na indústria farmacêutica portuguesa. Foram identificadas onze empresas portuguesas com unidades de produção em Portugal e todas participaram na presente investigação. Nove casos de estudo foram selecionados, considerando o acesso a ambos os lados do relacionamento e a riqueza dos dados recolhidos. Os dados forarn obtidos sobretudo em entrevistas aprofundadas e foram complementados com observação e com dados secundários. Os dados qualitativos foram tratados através de urn processo analítico que envolve compilação, desagregação, remontagem, interpretação e conclusão. A interação entre concorrentes pode ser caracterizada através de quatro dimensões: contexto, natureza, processos de interação e resultados. 0 papel do contexto partilhado, do grau de coopetição (ao·nível da empresa e do departamento), da troca de informação, dos processos de coordenação e dos laços criados está fortemente relacionado com a interação e o desenvolvimento do relacionamento horizontal. 0 desenvolvimento do relacionamento entre concorrentes pode conter cinco fases: co-existência, formação, desenvolvimento, dormência e dissolução. É identificada a presença de um catalisador (e.g. agência governamental) que induz o desenvolvimento do relacionamento entre concorrentes. 0 desenvolvimento de relacionamentos entre concorrentes afeta o poder de negociação, os processos de intemacionalização e o desenvolvimento de relacionamentos público-privados.
Horizontal relationships, such as strategic alliances, are of increasing importance and prevalence. The purpose of this research is to understand horizontal relationships ' development within an interaction and network perspective. Significant research has been carried out on strategic alliances, focusing on motivations, antecedents, formation, and outcomes. However researchers have paid far less attention to the developmental processes of these business relationships. To tackle the research objective two complementary conceptual frameworks are considered, one, addressing the interaction and, another, the relationship development. This research, mainly supported by the industrial marketing and purchasing approach, focuses on: the interaction between competitors, the intercompetitor relationship development and the network effect of such business relationships. It is considered a multiple case study strategy within the Portuguese pharmaceutical industry. Eleven Portuguese pharmaceutical companies with production facilities in-country were identified and all participated in the present research. Nine case studies were purposefully selected, considering the access to both sides of the intercompetitor relationship and the intensive and rich information within. Data was collected mainly through in-depth inteniiews and complemented by observation and secondary data. The qualitative data·· was examined adopting the analytical process of compiling, disassembling, reassembling, interpreting and concluding. Intercompetitor interaction can be characterized along four linked dimensions: context, nature, interaction processes and outcomes. The role of the relationship shared context, coopetition degree (at the company and department levels), informat.ion exchange, coordination processes and bond development is strongly related with the·interaction and the development of the horizontal relationship. The intercompetitor relationship development may comprise five main phases: co-existence, formation, development, dormant and dissolution. The presence of a catalyst (e.g. government body) triggering the intercompetitor relationship development is denoted. The development of relationships between competitors affects the companies' negotiation power, the internationalization processes and the public-private relationships development.
APA, Harvard, Vancouver, ISO, and other styles
10

蕭雪玲 and Suet-ling Celine Siu. "Business strategy of Johnson & Johnson." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1996. http://hub.hku.hk/bib/B31267646.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pharmaceutical industry Australia Case studies"

1

Science, politics, and the pharmaceutical industry. London: UCL Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tapon, Francis. Case studies on the organization of pharmaceutical R & D: A preliminary report. [Toronto]: Ontario Centre for International Business Research Programme, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Barbosa, Alexandre de Freitas. A indústria farmacêutica brasileira e as exportações para a América Latina: Impactos dos acordos comerciais e das variáveis macroeconômicas. Brasília, DF, Brasil: Federação Brasileira da Indústria Farmacêutica, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Monte Carlo simulation for the pharmaceutical industry: Concepts, algorithms, and case studies. Boca Raton: CRC Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

P, Millard Steven, and Krause Andreas, eds. Applied statistics in the pharmaceutical industry: With case studies using S-Plus. New York: Springer, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Donghi, Monica. Patent strategy in pharmaceutical industry: Are additional patents valuable? Baden-Baden: Nomos, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zucker, Lynne G. Present at the revolution: Transformation of technical identity for a large incumbent pharmaceutical firm after the biotechnological breakthrourgh. Cambridge, MA: National Bureau of Economic Research, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Innovation in the making. Frederiksberg, Denmark: Samfundslitteratur, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hide, Martin S. The management of buyer-supplier relationships in the pharmaceutical industry: A case study. Dublin: University College Dublin, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

N, Denoncourt Rena, and Warner Anjli C, eds. U.S. vaccine markets: Overview and four case studies. Washington, D.C: AEI Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pharmaceutical industry Australia Case studies"

1

Diodone, Ralph, Pirmin C. Hidber, Michael Kammerer, Roland Meier, Urs Schwitter, and Jürgen Thun. "Industry Case Studies." In Polymorphism in the Pharmaceutical Industry, 447–68. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2018. http://dx.doi.org/10.1002/9783527697847.ch15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Huggins, Seth, Andrew Cosbie, and John Gaertner. "FILTRATION CASE STUDIES." In Chemical Engineering in the Pharmaceutical Industry, 833–45. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2019. http://dx.doi.org/10.1002/9781119600800.ch36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gaertner, John, Nandkishor K. Nere, James C. Marek, Shailendra Bordawekar, Laurie Mlinar, Moiz Diwan, and Lei Cao. "DRYING CASE STUDIES." In Chemical Engineering in the Pharmaceutical Industry, 847–60. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2019. http://dx.doi.org/10.1002/9781119600800.ch37.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nere, Nandkishor K., Moiz Diwan, Ann M. Czyzewski, James C. Marek, Kushal Sinha, and Huayu Li. "CASE STUDIES ON CRYSTALLIZATION SCALE-UP." In Chemical Engineering in the Pharmaceutical Industry, 617–33. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2019. http://dx.doi.org/10.1002/9781119600800.ch27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mlinar, Laurie, Kushal Sinha, Elie Chaaya, Subramanya Nayak, and Andrew Cosbie. "CASE STUDIES ON THE USE OF DISTILLATION IN THE PHARMACEUTICAL INDUSTRY." In Chemical Engineering in the Pharmaceutical Industry, 787–97. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2019. http://dx.doi.org/10.1002/9781119600800.ch34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

LaPorte, Thomas L., Chenchi Wang, and G. Scott Jones. "Process Development and Case Studies of Continuous Reactor Systems for Production of API and Pharmaceutical Intermediates." In Chemical Engineering in the Pharmaceutical Industry, 437–55. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.1002/9780470882221.ch23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

LaPorte, Thomas L., Chenchi Wang, and G. Scott Jones. "PROCESS DEVELOPMENT AND CASE STUDIES OF CONTINUOUS REACTOR SYSTEMS FOR PRODUCTION OF API AND PHARMACEUTICAL INTERMEDIATES." In Chemical Engineering in the Pharmaceutical Industry, 319–39. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2019. http://dx.doi.org/10.1002/9781119600800.ch14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Ji, and Berkeley W. Cue. "Green Process Chemistry in the Pharmaceutical Industry: Recent Case Studies." In Green Techniques for Organic Synthesis and Medicinal Chemistry, 631–58. Chichester, UK: John Wiley & Sons, Ltd, 2012. http://dx.doi.org/10.1002/9780470711828.ch24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fortunak, Joseph M., Ji Zhang, Frederick E. Nytko, and Tiffany N. Ellison. "Green Process Chemistry in the Pharmaceutical Industry: Case Studies Update (2012-2016)." In Green Techniques for Organic Synthesis and Medicinal Chemistry, 621–47. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119288152.ch23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dengleri, Klio, Petros Lois, Alkis Thrassou, and Spyridon Repousis. "Industry Application of Assessment and Forecasting Theories Through Comparative Financial Analysis: The Case of Greek Pharmaceutical Industries Under Crisis Conditions." In Palgrave Studies in Cross-disciplinary Business Research, In Association with EuroMed Academy of Business, 175–98. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17523-8_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical industry Australia Case studies"

1

Kennedy, Tom, Mark Muggeridge, and Scott Pearce. "Netcasting – Case Studies in the Industry." In SMPTE Australia Conference. IEEE, 1999. http://dx.doi.org/10.5594/m001185.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cui, Linlin, Jin Dong, and Yueting Chai. "Quantitative Studies on the Organizational Structure of SME's: A Case Study of the Pharmaceutical Industry in China." In 2006 Winter Simulation Conference. IEEE, 2006. http://dx.doi.org/10.1109/wsc.2006.323059.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hada, Izabela Diana. "Analysis and Evolution of Profitability in the Pharmaceutical Field in Romania." In International Conference Innovative Business Management & Global Entrepreneurship. LUMEN Publishing, 2020. http://dx.doi.org/10.18662/lumproc/ibmage2020/55.

Full text
Abstract:
The pharmaceutical industry is an important field of activity that contributes to the diagnosis, treatment, maintenance of the health of the population. The need of pharmaceuticals has led to an increase in both the number of drug manufacturers and the number of distributors. A significant part of the specialized studies deals with the problem of the profitability of the pharmaceutical industry. The study of the financial performance of the economic entities in the pharmaceutical field in Romania is a necessary concern in the conditions of a progressive annual increase of the profitability of this sector. The main purpose of this paper is the analysis and presentation of the evolution of profitability indicators (return on assets, return on capital, return on sales) as part of the activity of assessing the financial performance of economic entities operating in Romania in the pharmaceutical industry (manufacturing of basic pharmaceutical products - CAEN code 2110). Profitability indicators were analyzed for a number of 46 entities in the pharmaceutical industry in Romania for a period of 20 years (1999-2018). We are talking in this case about a turnover of 1.1 Billion lei (249.2 million euros), a number of employees of 3,098 employees, a profit of 135.2 million lei (30.7 million euros) - representing 0.12% of the net profit made in Romania. The research results show that in the period 2008-2009, the financial crisis left a strong mark on the evolution of profitability in the pharmaceutical industry. However, during the 20 years we talk about a positive evolution, in the sense of increasing the profitability of this field, which justifies the increase in the consumption of pharmaceuticals products.
APA, Harvard, Vancouver, ISO, and other styles
4

Liner, Barry, and Christopher Stacklin. "Driving Water and Wastewater Utilities to More Sustainable Energy Management." In ASME 2013 Power Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/power2013-98310.

Full text
Abstract:
The Water Environment Federation (WEF) and industry leaders have identified the need for an energy roadmap to guide utilities of all sizes down the road to overall sustainable energy management through increased renewable energy production and energy conservation. This roadmap leverages a framework developed by the electric power sector. Known as the The Smart Grid Maturity Model (SGMM), the framework moved the industry toward “Smart Grid” technology. The basis of the Energy Roadmap originated at a workshop of water and power industry leaders convened by WEF in North Carolina in March 2012. Case studies were analyzed from successful utilities in Austria, Holland, Australia, and the United States. High level, strategic best practices were identified and organized into topic areas, which define the level of progression (enable, integrate and optimize) towards achieving energy sustainability. As a living document, the roadmap is always under review by dedicated groups within the industry. A number of utilities worldwide have already taken the leap and begun this transformation towards resource recovery and many more are peering over the edge. The WEF Energy Roadmap is intended to guide utilities of all sizes as they progress toward becoming treatment plants of the future. While it is not practical for all wastewater treatment plants to become energy positive or neutral, all can take steps towards increasing energy sustainability. A key component of the WEF Energy Roadmap is collaboration between water/wastewater utilities and electric utilities. This paper focuses on lessons learned and case studies about energy and water utilities working together to address energy-water nexus challenges. This paper examines perspectives both from energy use at water sector facilities and water use at energy sector facilities.
APA, Harvard, Vancouver, ISO, and other styles
5

Sheil, Henry, and Peter Young. "Challenging the Need for Dual Gas Production Flowline Systems Using Emerging Hydrate Remediation Intervention Technology." In ASME 2011 30th International Conference on Ocean, Offshore and Arctic Engineering. ASMEDC, 2011. http://dx.doi.org/10.1115/omae2011-49191.

Full text
Abstract:
Gas production flowlines are presenting flow assurance challenges in hydrate management resulting from low ambient seawater temperatures in an increasing number of deepwater developments. During operation the equilibrium hydrate temperature of the produced fluid may be above the minimum seabed temperature, and hence there is a risk of hydrate blockage in the subsea system should the hydrate inhibition system fail. The continuous injection of MEG, with little or no insulation of the subsea system, is a common hydrate mitigation strategy for a gas production system. If insufficient inhibitor is injected there is a risk of hydrates forming and potential blockage of the pipeline in parts of the field. The industry-preferred approach for hydrate blockage remediation is Dual Sided Depressurisation (DSD). The objective is to depressurise the flowline to below hydrate onset conditions, allowing hydrate dissociation and safely disposing of the gas inventory. This is typically performed by one of two methods; installation of a dual flowline system for facility based depressurisation (with CAPEX implications); or a Mobile Offshore Drilling Unit (MODU) can be connected to an appropriate point upstream of the blockage to allow simultaneous depressurisation at the MODU and the facility (with OPEX implications). It is recognised that either method incurs significant costs. Typically the cost and time uncertainties of bringing in a MODU to solve these production stoppages is unattractive. Consequently subsea gas developments have often incurred the increased CAPEX of providing dual flowlines to permit DSD from the facility. An optimisation of the MODU-based intervention method is the subject of this paper. The feasibility of using a “lightweight” intervention vessel (for example an Offshore Support Vessel) in place of the MODU to depressurise the flowline is discussed. This paper discusses hydrate remediation difficulties and case studies; presents emerging hydrate remediation methods and briefly introduces vessel requirements. In discussing this optimisation, this paper also presents an introduction to hydrate remediation theory, some practical challenges, case studies and vessel requirements. The study concluded: • Significant CAPEX reductions may be achieved by adopting the outlined strategy; namely avoiding dual flowline infrastructure, and ensuring a reduced response time and day rate for any hydrate remediation operations to be performed. • For this strategy to be adopted cost effectively, pre-engineering, along with suitable contractual arrangements, are required to make the necessary equipment and personnel resources readily available should a hydrate blockage occur. For assets in remote locations, e.g. Australia, making the resources available is a significant challenge. • Flowline system access for depressurisation may be achieved by two methods; via the subsea Christmas tree or via suitably located fluid injection/vent access point(s).
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Pharmaceutical industry Australia Case studies"

1

Marshall, Amber, Krystle Turner, Carol Richards, Marcus Foth, Michael Dezuanni, and Tim Neale. A case study of human factors of digital AgTech adoption: Condamine Plains, Darling Downs. Queensland University of Technology, December 2021. http://dx.doi.org/10.5204/rep.eprints.227177.

Full text
Abstract:
As global agricultural production methods and supply chains have become more digitised, farmers around the world are adopting digital AgTech such as drones, Internet of Things (IoT), remote sensors, blockchain, and satellite imagery to inform their on-farm decision-making. While early adopters and technology advocates globally are spruiking and realising the benefits of digital AgTech, many Australian farmers are reluctant or unable to participate fully in the digital economy. This is an important issue, as the Australian Government has said that digital farming is essential to meeting its target of agriculture being a $100billion industry by 2030. Most studies of AgTech adoption focus on individual-level barriers, yielding well-documented issues such as access to digital connectivity, availability of AgTech suppliers, non-use of ICTs, and cost-benefit for farmers. In contrast, our project took an ‘ecosystems’ approach to study cotton farmers in the Darling Downs region in Queensland, Australia who are installing water sensors, satellite imagery, and IoT plant probes to generate data to be aggregated on a dashboard to inform decision-making. We asked our farmers to map their local ecosystem, and then set up interviewing different stakeholders (such technology providers, agronomists, and suppliers) to understand how community-level orientations to digital agriculture enabled and constrained on-farm adoption. We identified human factors of digital AgTech adoption at the macro, regional and farm levels, with a pronounced ‘data divide’ between farm and community level stakeholders within the ecosystem. This ‘data divide’ is characterised by a capability gap between the provision of the devices and software that generate data by technology companies, and the ability of farmers to manage, implement, use, and maintain them effectively and independently. In the Condamine Plains project, farmers were willing and determined to learn new, advanced digital and data literacy skills. Other farmers in different circumstances may not see value in such an undertaking or have the necessary support to take full advantage of the technologies once they are implemented. Moreover, there did not seem to be a willingness or capacity in the rest of the ecosystem to fill this gap. The work raises questions about the type and level of new, digital expertise farmers need to attain in the transition to digital farming, and what interventions are necessary to address the significant barriers to adoption and effective use that remain in rural communities. By holistically considering how macro- and micro-level factors may be combined with community-level influences, this study provides a more complete and holistic account of the contextualised factors that drive or undermine digital AgTech adoption on farms in rural communities. This report provides insights and evidence to inform strategies for rural ecosystems to transition farms to meet the requirements and opportunities of Agriculture 4.0 in Australia and abroad.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical industry Australia Case studies' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography